Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System by Mucci, Juan Marcos & Rozenfeld, Paula
Review Article
Pathogenesis of Bone Alterations in Gaucher Disease:
The Role of Immune System
Juan Marcos Mucci and Paula Rozenfeld
IIFP, Departamento de Ciencias Biolo´gicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata y CONICET,
47 y 115, 1900 La Plata, Argentina
Correspondence should be addressed to Paula Rozenfeld; paurozen@biol.unlp.edu.ar
Received 8 October 2014; Revised 9 January 2015; Accepted 11 January 2015
Academic Editor: Giacomina Brunetti
Copyright © 2015 J. M. Mucci and P. Rozenfeld.This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the originalwork is properly cited.
Gaucher, the most prevalent lysosomal disorder, is an autosomal recessive inherited disorder due to a deficiency of glucocerebrosi-
dase. Glucocerebrosidase deficiency leads to the accumulation of glucosylceramide primarily in cells of mononuclear-macrophage
lineage. Clinical alterations are visceral, hematological, and skeletal. Bone disorder in Gaucher disease produces defects on bone
metabolism and structure and patients suffer from bone pain and crisis. Skeletal problems include osteopenia, osteoporosis,
osteolytic lesions, and osteonecrosis. On the other hand a chronic stimulation of the immune system is a well-accepted hallmark in
this disease. In this review we summarize the latest findings in the mechanisms leading to the bone pathology in Gaucher disease
in relationship with the proinflammatory state.
1. Osteoimmunology
A diverse number of interactions between bone and immune
cells occur within the bone microenvironment. Bone and
immune cells share the same progenitors residing in the bone
marrow and these progenitors are under the effect of the same
molecules including cytokines; these molecules can have a
high influence in the hematopoiesis process, local immune
responses, and bone cell development.
There is evidence that several immune cells can influ-
ence bone cell development and activity. However, the key
players in this regulation are activated T-cells. After suc-
cessful antigen-specific activation, T-cells produce a number
of proinflammatory cytokines [1] that can act directly or
indirectly on cells involved in bone turnover shifting bone
balance towards bone resorption or bone generation.
The bone turnover process involves bone removal by
resorbing osteoclasts and bone formation by osteoblasts.
These processes are strictly regulated in physiological condi-
tions, and this regulation implies the participation of osteo-
cytes, which are the final step of osteoblast differentiation [2].
Osteoclasts are bone resorbing cells that derive from the
same progenitors as macrophages and dendritic cells (mono-
cyte/macrophage lineage) [3]. RANKL and macrophage
colony stimulating factor (M-CSF) are essential for commit-
ment of the common precursor to the osteoclast lineage and
survival of differentiated osteoclasts. In addition numerous
cytokines are also able to influence osteoclast differentiation
and/or function [4].
Osteoblasts are the bone forming cells that originate from
bone marrow-residing multipotent mesenchymal stem cells.
Osteoblasts are one of the major sources of RANKL and
in this manner they control bone resorption. These cells
can influence immune cells and are critical regulators of the
hematopoietic stem cells (HSC) from where immune and
other blood cells derive [5].
RANKL is a transmembrane protein of the TNF super-
family encoded by the Tnfsf11 gene. It is expressed on the
surface of osteoblasts (at different stages of differentiation),
osteocytes, stromal cells of undefined origin, B- and T-cells,
synovial fibroblasts, hypertrophic chondrocytes, and even
osteoclasts themselves. The receptor of RANKL is RANK,
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which is encoded by the Tnfrsf11a gene. Upon stimulation of
RANK by RANKL under costimulatory signals such as M-
CSF, the process of osteoclast differentiation and maturation
begins [6]. The third protein member of the osteoclastoge-
nesis axis is called osteoprotegerin (OPG) and is encoded
by the Tnfrsf11b gene. OPG functions as a soluble decoy
receptor for RANKL, inhibiting RANKL interaction with
RANK, thus acting like an antiosteoclastogenic molecule [7].
OPG is expressed by osteoblasts and othermesenchymal cells
[8].
The RANK/RANKL/OPG axis is essential in osteoclast
differentiation in vivo as mutations in genes encoding
RANKL, RANK, or OPG lead to disorders with high bone
pathology [9]. RANKL is presented in two different forms
as a membrane-anchored molecule or as a soluble protein
released by the action of matrix metalloproteinases [10].
Both forms of the protein have osteoclastogenesis activity;
however, the membrane-anchored form functions more effi-
ciently [11].
The expression of RANKL on mesenchymal cells, such
as osteoblasts, is upregulated by osteoclastogenic factors such
as vitamin D3, prostaglandin E2, parathyroid hormone, and




The activation of immune cells is a requisite for defense of the
host against pathogens; however, a persistent overactivation
of effector cells under certain pathological conditions can
result in tissue damage.
In the early 1980s, osteoclasts were identified throughout
the synovium and at the synovium/bone interface in joints of
rheumatoid arthritis (RA) patients [13]. These observations
led to the determination that osteoclasts play an important
role in certain pathological conditions [14, 15].
Inflammatory cytokines such as IL-1, IL-6, and TNF-𝛼 are
present at high levels in the synovial fluid and synovium of
RA patients.These cytokines have a potent capacity to induce
the expression of RANKL on synovial fibroblasts and bone
derived stromal cells and to affect osteoclast differentiation,
thus directly contributing to the bone destruction process
[13].
Osteoporosis (OP) has been traditionally considered as
an endocrine disease resulting mainly from the estrogens
decline after menopause. This change affects bone remodel-
ing, leading to higher risk of fractures. Since the endocrine
point of view by itself does not completely explain the patho-
genesis of OP, the osteoimmunological approach raised and
suggested that the production of proinflammatory cytokines
such as TNF-𝛼, IL-1, IL-6, IL-7, and IFN-𝛾 by activated
T lymphocytes could contribute to menopausal changes in
bone dynamics [16, 17].
Phenylketonuria (PKU) is an inborn error of amino
acid metabolism resulting from deficiency of phenylalanine
hydroxylase, the key enzyme for phenylalanine metabolism.
Bone impairment has been widely documented in PKU,
using both radiological and ultrasound methods [18, 19],
and it is typically associated with increasing age. In 2010 it
was shown that PKU patients present increased numbers of
circulating osteoclast precursors with higher differentiation
potential compared to healthy controls. TNF-𝛼 levels and
the RANKL/OPG ratio were increased in supernatants of
PBMC cultures from patients and it was shown that the
increased osteoclast differentiation from PBMC was RANKL
dependent [20].
3. Gaucher Disease
Gaucher disease is the most prevalent lysosomal disorder
[21], of around 1 : 13,000–60,000, and with a higher frequency
in the Ashkenazi Jewish population [22]. Gaucher disease
(GD;MIM#230800) is an autosomal recessive inherited lyso-
somal storage disorder that is due to a deficiency of glucocere-
brosidase (acid beta glucosidase; GCase; EC 3.2.1.45). GCase
deficiency results in progressive, intralysosomal accumula-
tion of glucosylceramide in different tissues, primarily in cells
of mononuclear-macrophage lineage. Lipid accumulation in
macrophages results in engorged cells called “Gaucher cells.”
Rarely, a variant GDmay be secondarily caused by deficiency
of the saposin C, the activator of the enzyme [23].
The first specific treatment for a lysosomal disorder was
introduced for Gaucher disease, the enzyme replacement
therapy (ERT) [24].
Clinical phenotype of GD reflects a continuum ranging
from neuronopathic forms (GD types II and III) to the more
frequent visceral form (GD type I) and from early onset to
late onset [25].
Type I is observed in 90% of cases and is characterized
by the lack of CNS manifestations. Clinical alterations are
visceral (hepatosplenomegaly without organ disfunction),
hematological (anemia and thrombopenia), and skeletal [26].
Bone pathology remains the main problem for GD
I patients after the introduction of enzyme replacement
therapy. Bone disease is a common and often painful and
disabling manifestation of GD. Multiple compartments of
bone that are affected are caused by alterations in bone
metabolism (turnover, remodeling, and mineralization).
Almost all GD patients develop skeletal complications,
consisting mainly of remodeling failure, osteopenia, osteo-
porosis, marrow infiltration, avascular necrosis, and oste-
olysis [27]. It may be suggested that patients with early
onset GD I are at risk of skeletal disease. One of the early
signs is the typical “Erlenmeyer flask” deformity of the
distal femur. These changes predominantly affect long bones
and the vertebrae. Patients could be asymptomatic with or
without radiological signs or present symptoms including
bone pain involving one limb or joint, avascular necrosis, or
pathological fractures. An international registry of Gaucher
patients worldwide revealed that 62% of them had some
form of radiologic bone disease and 43% experienced bone
pain [28]. The M𝜙 are prominent in the bone marrow and
contribute to acute episodes of osteonecrosis, particularly
during growth. Necrosis of the marrow leads to impaired
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function of joints. Other effects on the skeleton include local
swellings known as Gaucheromas.
Imaging methodologies for the evaluation of skeletal
involvement, such as conventional (plain) radiography and
scintigraphy, MRI, computed tomography, or dual energy
X-ray absorptiometry, are currently employed and provide
accurate evaluation and staging of bone lesions in GD [29].
Much evidence demonstrates substantial improvement of
hematological and visceral parameters upon introduction of
specific ERT for Gaucher patients [30]. However, bone tissue
does not respond equally; it is, in some degree, refractory
to therapy. Patients at risk may benefit from early inter-
vention with ERT, although many lesions and osteonecrosis
are irreversible. Enzyme therapy cannot reverse established
osseous injury [31]. Several prospective studies have been
performed to evaluate the effectiveness of ERT in treating
skeletal pathology. Bone pain is present at baseline in around
two-thirds of the patients. Some patients improve in this
aspect, but 40% of patients remain with this symptom after
18 months of treatment. In a recent study of patients treated
with imiglucerase for 10 years, a positive effect was observed
in skeletal symptoms, as well as a reduction of bone pain and
crises in patients who suffer from them at baseline.Moreover,
most of the patients who did not report bone symptoms at
baseline continued to be pain-free after 10 years of ERT [32].
Bone mineral density tends to increase during therapy,
but the response is slow [31]. Patients with preexistent skeletal
complications tend to suffer incidents during ERT, such as
medullary infarctions, avascular necrosis, or fractures, but
the frequency of these events is reduced [33]. Low bone
density manifests early in children with GD, and mineral
density deficit ismaximal in the adolescent period.Moreover,
this group is most responsive to ERT, underscoring the
importance of early diagnosis and intervention to achieve
optimal peak bonemass [34]. In the largest study with treated
pediatric patients bone mineral health was impaired in a
large proportion of the group before ERT and improved
considerably with treatment [35].
4. Inflammation in Gaucher Disease
A chronic stimulation of the immune system is a well-
accepted hallmark in GD. Studies of the proinflammatory
state in patients were mainly focused on analyzing cytokine
levels in sera [36–38]. Although there is a high variation
among patients, increased levels of IL-1𝛼, IL-1𝛽, IL-1Ra, sIL-
2R, IL-6, IL-8, IL-10, IL-18, TNF-𝛼, TGF-𝛽, M-CSF, MIP-1,
and CCL18 have been reported in sera [39–41].
Macrophages (M𝜙) are the principal cell type compro-
mised in patients with GD. M𝜙 have several different func-
tions including tissue remodeling and host defense; on the
other hand they play central roles in many disease processes.
They can secrete both anti- or proinflammatory cytokines
depending on the activation signals. Upon activation, two
main phenotypes of M𝜙 could be produced: classical or
alternative, depending on environment present at the time
of the stages of activation [42]. Gaucher cells resemble
alternative activatedM𝜙 [43], characterized by the expression
of chitotriosidase and CCL18.
Several immune cells have been shown to be impaired
in GD including monocytes, M𝜙, dendritic cells, and T- and
B-cells [44–46]. It has been shown that monocytes in GD
patients expressed higher levels of CD1d andMHCII on their
surface, which could lead to an increased T-cell activation
[47]. Abnormalities in the B-cell subset are mainly IgG and
IgM hypergammaglobulinemia and plasmacytosis [48]. An
increased incidence of gammopathies and multiple myeloma
has been reported, further showing the interplay between
Gaucher cells and the immune system [49].
A GD murine model was generated, in which the GBA
gene was conditionally deleted on hematopoietic cells [50].
This model presented all the hallmark characteristics of GD
I, including organomegaly, and it was the only murine model
so far to show bone involvement. In this model an alteration
of immune cell compartment was observed. This alteration
included thymicmaturation impairment with higher levels of
CD4+ and antigen-presenting cells. What is more, activated
B-cells on the thymus were also increased, which could
explain the alteration of normal T-cell maturation [51].
In another murine model of GD, higher levels of CD4+
cells were found on the lungs, spleen, and liver as well as an
increased expression of costimulatorymolecules [52]. Higher
levels of proinflammatory cytokines including IFN-𝛾, IL-
12p40, TNF-𝛼, IL-17A/F, IL-6, and TGF-𝛽 were found in sera
of these mice. When T-cells were cocultured with dendritic
cells in the presence of glucosylceramide, higher levels of
Th1/Th17 cytokines were secreted.
More recently, using a different approach, Panicker et al.
differentiatedM𝜙 frompatient induced pluripotent stem cells
(hiPSC); with this model they showed increased production
of IL-1𝛽, TNF-𝛼, and IL-6 by GD derived M𝜙 and an
exacerbated response to LPS treatment [53].
This deregulation of immune system cells is tightly related
to the increased levels of cytokines and chemokines. These
molecules are secreted by the immune cells, which, in turn,
are recruited and activated by chemokines and cytokines,
respectively. This could create a loop in which immune
cells from Gaucher patients are being continuously activated,
leading to systemic and focal activation of the immune
system.
5. Osteoclast-Osteoblast Uncoupling in
Gaucher Disease
The molecular and cellular bases of GD bone physiopathol-
ogy are not well understood and opposing studies have
emerged in the last few years. As mentioned before in 2010,
Mistry et al. [50] generated a conditional KO mouse model
of GD I which presented the main GD clinical hallmarks.
The most striking feature about this model is the presence
of bone involvement as previous mouse models of GD did
not present bone involvement. Bone manifestations included
medullar infarctions with associated avascular necrosis and
osteopenia at all sites. The bone formation rate presented
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a significant impairment in these mice while the quantifica-
tion of TRAP-labeled surfaces did not present differences.
A significant impairment in osteoblast proliferation and
differentiation was present in the model, while osteoclast
differentiation and activity did not seem to be altered.
The impairment on osteoblast proliferation was shown to
be dependent on a decrease in PKC activity due to the
accumulation of glucosylsphingosine and, to a lesser extent,
glucosylceramide. More recent studies present sphingosine
as the most probable candidate for osteoblast impairment
in the mouse model [54]. These findings suggest that bone
complications in GD would result from an osteoblast source
without osteoclast involvement [50, 54].
Different reports have shown the involvement of osteo-
clasts on GD bone pathophysiology. Using an in vitro model
of GD in whichmesenchymal stem cells andmonocytes were
exposed to conduritol-𝛽-epoxide (CBE), a specific glucocere-
brosidase inhibitor, Lecourt et al. showed that although direct
CBE treatment had no effect on osteoclast differentiation if
mesenchymal stem cells were cultured in the presence of con-
ditioned media from CBE-exposed monocytes, an increased
osteoclastogenesis and resorption activity was detected [55].
Our group showed, using a similar approach, that treat-
ment of osteoclast precursors with conditioned media from
peripheral blood mononuclear cells (PBMCs) exposed to
CBE resulted in an increased level of osteoclast differentiation
when compared to control conditioned media.
What is more, we showed that one of the central
molecules involved in the increased osteoclast differentiation
was the proinflammatory cytokine TNF-𝛼 and that T-cells
also played an important role in this process [56]. The
same results were obtained using a mice model in which
conditioned media were obtained from peritoneal M𝜙 or
splenocytes exposed to CBE; in this model involvement of
TNF-𝛼 was also shown using osteoclast precursors derived
from TNF-𝛼 receptor deficient mice [57]. In addition to
this we could show that treatment of the osteoblastic cell
line MC3T3 with conditioned media from CBE treated M𝜙
reduced mineralization and collagen deposit [57]. These
results would indicate an impairment of both osteoclast
and osteoblast activity in GD leading to bone loss as the
involvement of immune cells and molecules in this process.
The group of Reed et al. isolated PBMC from patients
withGD and showed that patients’ monocytes, when exposed
to osteoclastogenic mediators, presented a higher differen-
tiation towards active osteoclasts. What is more, osteoclasts
differentiated from patients had bigger diameter and a
greater number of nuclei when compared with osteoclasts
differentiated from healthy controls’ PBMCs. They showed
that the higher osteoclastogenic potential presented a clinical
correlation with patient’s bone involvement [58].
6. Future Perspectives
GD is the most common lysosomal disorder and the first for
which specific treatment has been developed. Bone disease
in Gaucher patients is one of the most disabling features of
the disease, so the possibility of knowing the mechanisms
underlying the bone pathology is a main challenge to ame-
liorate the quality of life of patients.
Studies are based on the explanation of the cellular and
molecular pathways that result upon glucosylceramide accu-
mulation in M𝜙 and the possible relationship with different
bone cells.
The bases of osteoimmunology are being applied to bring
light in this aspect. In this regard, there are several questions
to be answered. T-cell involvement and a better under-
standing of the effects and importance of proinflammatory
cytokines such as TNF-𝛼 on bone pathology in GD are
necessary.
On the other hand, crosstalk between osteoblasts and
osteoclasts in GD could provide new mechanisms involved
in the process of bone loss.
Finally the effect of ERT and substrate reduction therapy
on bone involvement is a central aspect to be studied,
especially, how these treatments affect different bone cells and
their function.
The results of basic research will be of utility in order to
identify new targets for coadjuvant therapies to treat skeletal
pathology in GD.
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